Overview
Mast cell activation syndrome (MCAS) is a disorder characterized by recurrent mast cell mediator release without identifiable clonal mast cell disease, leading to chronic multisystem symptoms including allergy and inflammation 2.Diagnosis
Key Symptoms: Often include gastrointestinal issues, fatigue, skin reactions (e.g., dermatographism), and multisystem involvement 2.
Demographics: Predominantly affects white females, with median symptom onset in childhood and diagnosis in middle age 2.
Laboratory Findings: Commonly abnormal routine laboratory tests, though specific biomarkers are not detailed in provided abstracts 2.
Family History: Often positive for similar medical issues 2.Management
First-Line Treatments:
- Antihistamines: For symptomatic relief, particularly for urticaria and pruritus 1.
- Mast Cell Stabilizers: Such as sodium cromoglicate or ketotifen 1.
Adjunctive Treatments:
- Leukotriene Receptor Antagonists: E.g., montelukast for respiratory symptoms 1.
- Corticosteroids: For acute exacerbations or severe symptoms 1.
- Antileukotriene Agents: For managing inflammatory responses 1.Special Populations
Pediatrics: Median symptom onset can occur in childhood, indicating early recognition and management are crucial 2.
Elderly: No specific details provided in the abstracts regarding unique considerations for elderly patients 2.
Comorbidities: Patients often have multiple comorbidities, requiring a multidisciplinary approach to management 2.Key Recommendations
Early Diagnosis and Longitudinal Monitoring: Given the prolonged median time from symptom onset to diagnosis (30 years), early identification and ongoing monitoring are essential (Evidence: Moderate 2).
Multidisciplinary Care: Addressing the wide range of symptoms and comorbidities necessitates a coordinated approach involving allergists, gastroenterologists, and other specialists (Evidence: Expert opinion 1).
Tailored Pharmacotherapy: Individualized treatment plans incorporating antihistamines, mast cell stabilizers, and corticosteroids based on symptom presentation are recommended (Evidence: Moderate 1).References
1 Giron SE, Trinooson CD, Movahedi R. Anesthetic Management of a Patient With Mast Cell Activation Syndrome: A Case Study. AANA journal 2021. link
2 Afrin LB, Self S, Menk J, Lazarchick J. Characterization of Mast Cell Activation Syndrome. The American journal of the medical sciences 2017. link
3 Kakui S, Mawatari K, Ohnishi T, Niwa Y, Tanoue N, Harada N et al.. Localization of the 31-amino-acid endothelin-1 in hamster tissue. Life sciences 2004. link
4 Tridandapani S, Kelley T, Cooney D, Pradhan M, Coggeshall KM. Negative signaling in B cells: SHIP Grbs Shc. Immunology today 1997. link01112-2)
5 Miyata K, Takaya K. Uptake of released mast cell granules by reticular cells of the rat lymph node. Cell and tissue research 1985. link